Overview
MRNA market data
Price History
MRNA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$7.25 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.96 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -141.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $22.28 – $85.60 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $25.2B · P/B 1.33 · P/S 11.30.
Company News
Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All ChildrenBenzinga · Aug 10, 2026, 7:00 PM
Global Influenza Vaccine Market Report, 2026 Edition - Profiles GlaxoSmithKline, Pfizer, Sanofi, Moderna, and 9 Other PlayersGlobenewswire Inc · Aug 7, 2026, 11:00 AM
Beyond COVID: Moderna Wins FDA Approval for Its Seasonal Flu VaccineBenzinga · Aug 6, 2026, 3:06 PM
Moderna shares are trading higher after the company announced FDA approval for mFLUSIVA.Benzinga · Aug 6, 2026, 11:38 AM
Reported Earlier, Moderna's mFLUSIVA Wins FDA Approval As First mRNA-Based Flu Vaccine For Adults 50 And OlderBenzinga · Aug 6, 2026, 7:25 AM
Moderna Advances Ebola Vaccine Into Human TestingBenzinga · Aug 5, 2026, 9:47 AM
Moderna Vaccinates First Patients In Its Phase 1 Clinical Trial Of mRNA-1469 To Treat Bundibugyo Ebolavirus Following Health Canada ApprovalBenzinga · Aug 4, 2026, 3:02 PM
Citigroup Maintains Neutral on Moderna, Raises Price Target to $60Benzinga · Aug 3, 2026, 6:42 PM
Moderna shares are trading lower after the company announced that its norovirus vaccine candidate, mRNA-1403, did not meet Phase 3 success criteria and it is preparing to enrol an additional cohort.Benzinga · Jul 31, 2026, 6:36 PM
Moderna Burns Cash, Suffers Fresh Vaccine SetbackBenzinga · Jul 31, 2026, 3:23 PM